{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:57:33Z","timestamp":1793383053502,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004351","name":"Sultan Qaboos University","doi-asserted-by":"publisher","award":["IG\/MED\/\/PHAR\/17\/01"],"award-info":[{"award-number":["IG\/MED\/\/PHAR\/17\/01"]}],"id":[{"id":"10.13039\/501100004351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00210-018-1564-7","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T16:58:29Z","timestamp":1536685109000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice"],"prefix":"10.1007","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-1784","authenticated-orcid":false,"given":"Aly M.","family":"Abdelrahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuf","family":"Al Suleimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asem","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Ashique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarsini","family":"Manoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahim","family":"Nemmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badreldin H.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"1564_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/jat.1465","volume":"30","author":"AM Abdelrahman","year":"2010","unstructured":"Abdelrahman AM, Al Salam S, AlMahruqi AS, Al husseni IS, Mansour MA, Ali BH (2010) N-acetylcysteine improves renal hemodynamics in rats with cisplatin-induced nephrotoxicity. J Appl Toxicol 30:15\u201321","journal-title":"J Appl Toxicol"},{"key":"1564_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biopha.2018.03.176","volume":"103","author":"AF Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab AF, Bamagous GA, Al-Harizy RM, ElSawy NA, Shahzad N, Ibrahim IA, Ghamdi SSA (2018) Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Biomed Pharmacother 103:59\u201366","journal-title":"Biomed Pharmacother"},{"key":"1564_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.fct.2009.09.030","volume":"48","author":"YM Suleimani Al","year":"2010","unstructured":"Al Suleimani YM, Abdelrahman AM, AlMahruqi AS, Alhseini IS, Tageldin MH, Mansour ME, Ali BH (2010) Interaction of nimesulide, a cyclooxygenase-2 inhibitor, with cisplatin in normotensive and spontaneously hypertensive rats. Food Chem Toxicol 48:139\u2013144","journal-title":"Food Chem Toxicol"},{"key":"1564_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.fct.2006.01.013","volume":"44","author":"BH Ali","year":"2006","unstructured":"Ali BH, Al Moundhri MS (2006) Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 44:1173\u20131183","journal-title":"Food Chem Toxicol"},{"key":"1564_CR5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1742-7843.2011.00724.x","volume":"109","author":"BH Ali","year":"2011","unstructured":"Ali BH, Abdelrahman AM, Al-Salam S, Sudhadevi M, AlMahruqi AS, Al-Husseni IS, Beegam S, Dhanasekaran S, Nemmar A, Al-Moundhri M (2011) The effect of sildenafil on cisplatin nephrotoxicity in rats. Basic Clin Pharmacol Toxicol 109:300\u2013308","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1564_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S0270-9295(03)00089-5","volume":"23","author":"I Arany","year":"2003","unstructured":"Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460\u2013464","journal-title":"Semin Nephrol"},{"key":"1564_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB (2014) Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8:262\u2013275","journal-title":"J Am Soc Hypertens"},{"issue":"7","key":"1564_CR8","doi-asserted-by":"publisher","first-page":"e0158810","DOI":"10.1371\/journal.pone.0158810","volume":"11","author":"Y-K Chang","year":"2016","unstructured":"Chang Y-K, Choi H, Jeong JY, Na K-R, Lee KW, Lim BJ, Choi DE (2016) Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS ONE 11(7):e0158810. https:\/\/doi.org\/10.1371\/journal.pone.0158810","journal-title":"PLoS ONE"},{"issue":"11","key":"1564_CR9","doi-asserted-by":"publisher","first-page":"e0188797","DOI":"10.1371\/journal.pone.0188797","volume":"12","author":"PK Chatterjee","year":"2017","unstructured":"Chatterjee PK, Yeboah MM, Solanki MH, Kumar G, Xue X, Pavlov VA, Al-Abed Y, Metz CN (2017) Activation of the cholinergic anti-inflammatory pathway by GTS-21 attenuates cisplatin-induced acute kidney injury in mice. PLoS ONE 12(11):e0188797. https:\/\/doi.org\/10.1371\/journal.pone.0188797","journal-title":"PLoS ONE"},{"key":"1564_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22:609\u2013619","journal-title":"Oncologist"},{"key":"1564_CR11","doi-asserted-by":"publisher","unstructured":"Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2017.12.027","DOI":"10.1016\/j.kint.2017.12.027"},{"key":"1564_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.taap.2017.05.034","volume":"329","author":"YC Huang","year":"2017","unstructured":"Huang YC, Tsai MS, Hsieh PC, Shih JH, Wang TS, Wang YC, Lin TH, Wang SH (2017) Galangin ameliorates cisplatin-induced nephrotoxicity by attenuating oxidative stress, inflammation and cell death in mice through inhibition of ERK and NF-kappaB signaling. Toxicol Appl Pharmacol 329:128\u2013139","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"1564_CR13","doi-asserted-by":"publisher","first-page":"e0179960","DOI":"10.1371\/journal.pone.0179960","volume":"12","author":"W Ji","year":"2017","unstructured":"Ji W, Zhao M, Wang M, Yan W, Liu Y, Ren S, Lu J, Wang B, Chen L (2017) Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS One 12(6):e0179960. https:\/\/doi.org\/10.1371\/journal.pone.0179960 eCollection 2017","journal-title":"PLoS One"},{"key":"1564_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/ki.2012.64","volume":"82","author":"J Kim","year":"2012","unstructured":"Kim J, Long KE, Tang K, Padanilam BJ (2012) Poly (ADP- ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int 82:193\u2013203","journal-title":"Kidney Int"},{"key":"1564_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1292\/jvms.12-0154","volume":"75","author":"Y Kimoto","year":"2013","unstructured":"Kimoto Y, Nishinohara M, Sugiyama A, Haruna A, Takeuchi T (2013) Protective effect of lactoferrin on cisplatin-induced nephrotoxicity in rats. J Vet Med Sci 75:159\u2013164","journal-title":"J Vet Med Sci"},{"issue":"6","key":"1564_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11906-015-0551-3","volume":"17","author":"JA Lovshin","year":"2015","unstructured":"Lovshin JA, Gilbert RE (2015) Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective. Curr Hypertens Rep 17(6):551. https:\/\/doi.org\/10.1007\/s11906-015-0551-3","journal-title":"Curr Hypertens Rep"},{"issue":"7","key":"1564_CR17","doi-asserted-by":"publisher","first-page":"e13228","DOI":"10.14814\/phy2.13228","volume":"5","author":"Q Ma","year":"2017","unstructured":"Ma Q, Steiger S, Anders H-J (2017) Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. Physiol Rep 5(7):e13228. https:\/\/doi.org\/10.14814\/phy2.13228","journal-title":"Physiol Rep"},{"key":"1564_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jash.2014.11.001","volume":"9","author":"G Maliha","year":"2015","unstructured":"Maliha G, Townsend RR (2015) SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens 9:48\u201353","journal-title":"J Am Soc Hypertens"},{"key":"1564_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","volume":"31","author":"S Manohar","year":"2018","unstructured":"Manohar S, Leung N (2018) Cisplatin nephrotoxicity: a review of the literature. J Nephrol 31:15\u201325","journal-title":"J Nephrol"},{"key":"1564_CR20","doi-asserted-by":"publisher","first-page":"3140680","DOI":"10.1155\/2017\/3140680","volume":"2017","author":"H Meng","year":"2017","unstructured":"Meng H, Fu G, Shen J, Shen K, Xu Z, Wang Y, Jin B, Pan H (2017) Ameliorative effect of daidzein on cisplatin-induced nephrotoxicity in mice via modulation of inflammation, oxidative stress, and cell death. Oxid Med Cell Longev 2017:3140680. https:\/\/doi.org\/10.1155\/2017\/3140680","journal-title":"Oxid Med Cell Longev"},{"key":"1564_CR21","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins 2:2490\u20132518. https:\/\/doi.org\/10.3390\/toxins2112490","journal-title":"Toxins"},{"key":"1564_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejphar.2016.11.028","volume":"794","author":"F Naznin","year":"2017","unstructured":"Naznin F, Sakoda H, Okada T, Tsubouchi H, Waise TM, Arakawa K, Nakazato M (2017) Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur J Pharmacol 794:37\u201344","journal-title":"Eur J Pharmacol"},{"key":"1564_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-0034-1395609","volume":"47","author":"A Ojima","year":"2015","unstructured":"Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S (2015) Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res 47:686\u2013692","journal-title":"Horm Metab Res"},{"key":"1564_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","volume":"8","author":"RV Oliva","year":"2014","unstructured":"Oliva RV, Bakris GL (2014) Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 8:330\u2013339","journal-title":"J Am Soc Hypertens"},{"key":"1564_CR25","doi-asserted-by":"publisher","first-page":"F835","DOI":"10.1152\/ajprenal.00285.2017","volume":"313","author":"CN Sharp","year":"2017","unstructured":"Sharp CN, Siskind LJ (2017) Developing better mouse models to study cisplatin-induced kidney injury. Am J Physiol Renal Physiol 313:F835\u2013F841","journal-title":"Am J Physiol Renal Physiol"},{"key":"1564_CR26","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1681\/ASN.V8101640","volume":"8","author":"D Sheikh-Hamad","year":"1997","unstructured":"Sheikh-Hamad D, Timmins K, Jalali Z (1997) Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine. J Am Soc Nephrol 8:1640\u20131645","journal-title":"J Am Soc Nephrol"},{"key":"1564_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00210-018-1469-5","volume":"391","author":"A Tahara","year":"2018","unstructured":"Tahara A, Takasu T (2018a) Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice. Naunyn Schmiedeberg\u2019s Arch Pharmacol 391:395\u2013406","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"1564_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejphar.2018.04.024","volume":"830","author":"A Tahara","year":"2018","unstructured":"Tahara A, Takasu T (2018b) Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. Eur J Pharmacol 830:68\u201375","journal-title":"Eur J Pharmacol"},{"key":"1564_CR29","doi-asserted-by":"publisher","first-page":"E563","DOI":"10.1152\/ajpendo.00086.2017","volume":"313","author":"L Tang","year":"2017","unstructured":"Tang L, Wu Y, Tian M, Sj\u00f6str\u00f6m CD, Johansson U, Peng XR, Smith DM, Huang Y (2017) Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab 313:E563\u2013E576","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1564_CR30","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2169\/internalmedicine.56.7196","volume":"56","author":"T Tosaki","year":"2017","unstructured":"Tosaki T, Kamiya H, Himeno T, Kato Y, Kondo M, Toyota K, Nishida T, Shiroma M, Tsubonaka K, Asai H, Moribe M, Nakaya Y, Nakamura J (2017) Sodium-glucose co-transporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes. Intern Med 56:597\u2013604","journal-title":"Intern Med"},{"key":"1564_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000480418","volume":"43","author":"H Yang","year":"2017","unstructured":"Yang H, Li W, Wang L, Li W, Sun H, He X, Zhang J (2017) The protective effects of sika deer antler protein on cisplatin-induced nephrotoxicity. Cell Physiol Biochem 43:395\u2013404","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"1564_CR32","doi-asserted-by":"publisher","first-page":"e0144640","DOI":"10.1371\/journal.pone.0144640","volume":"11","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Thai K, Kepecs DM, Gilbert RE (2016) Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS One 11(1):e0144640. https:\/\/doi.org\/10.1371\/journal.pone.0144640","journal-title":"PLoS One"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-018-1564-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-018-1564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-018-1564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T02:59:01Z","timestamp":1662001141000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-018-1564-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1007\/s00210-018-1564-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"24 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}